US-based precision oncology company Guardant Health has reported positive results from the Nile study of its blood test for identifying guideline-recommended biomarkers associated with first-line advanced non-small cell lung cancer (NSCLC).
The blood test, dubbed Guardant360, is designed to provide comprehensive genomic results.
When compared to standard tissue biopsy, Guardant’s assay was able to detect targetable genomic biomarkers at a similar rate, while delivering results in less time.
The NILE study enrolled 282 newly-diagnosed, advanced NSCLC patients, who underwent both tissue-based testing and Guardant360 assay.
Investigators compared the test for detection of EGFR, ALK, BRAF,RET, ROS1, MET and ERBB2 biomarkers, which are considered important for targeted treatment.
Guardant360 was able to identify the markers in 77 patients, while tissue testing detected markers in 60 participants. The blood test results were obtained in an average of nine days, compared to 15 days in case of tissue testing.
Findings also showed that for the four genetic changes (EGFR, ALK, ROS1, and BRAF) that are targeted by approved drugs, positive results with Guardant360 and the tissue biopsy were similar.
Guardant Health CEO Helmy Eltoukhy said: “This is an important new data set for clinical oncologists that we believe will further accelerate adoption of Guardant360 and, taken together with other recent independent investigations into Guardant360 in this clinical setting, solidifies the case for using blood first for treatment selection.”
Commenting on the results, the study’s senior author Vassiliki Papadimitrakopoulou said that the similar rate yet faster turn-around time indicates the use of liquid ahead of tissue for molecular testing in newly diagnosed advanced NSCLC patients.